Acurx Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2023

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of September 30, 2023 and December 31, 2022 were as follows:


	September 30, 2023		December 31, 2022
Accrued compensation expenses	$	206,812	$	542,895
Accrued research and development		2,973,770		1,405,536
Accrued professional fees		31,074		83,715
Other accounts payable and accrued expenses		11,722		29,539
Total	$	3,223,378	$	2,061,685